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Chronic obstructive pulmonary disease (COPD) diagnosis and subsequent management is 
largely based on clinical assessment which may lead to misdiagnosis that occurs, in 
particular, in primary care settings.1  Clinical assessment does not always accurately 
differentiate COPD from asthma or from asthma-COPD overlap leading inadequate 
treatment and increased risk of morbidity and mortality. 
Exhaled breath condensates (EBCs) are obtained by condensation of gases and droplets 
released during exhalation. Traditionally, pulmonologists focused on respiratory gases in 
these plumes, but it has been recently demonstrated the EBCs are rich sources of 
biomarkers and can reflect inflammation processes that are occurring within the lungs. 
However, biomarkers are often found a very low concentration.  
This study aims to establish the metabolomics signature of COPD and asthma 
patients using liquid chromatography hyphenated to high-resolution mass 
spectrometry. Such untargeted analysis will rely on a computer-assisted MS analysis tool 
(CAMSAT) called Finnee to mine for features of very low intensities (peaks) and measure 
key chromatographic parameters (intensities, migration time and accurate masses).2 
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 Figure 1: Schematic representation of the methodology developed for this work 
 
 The following methodologies were devised for this preliminary work: 
 
 EBC samples and clinical assessment 
EBCs from 15 patients (5 healthy, 5 with asthma symptoms and 5 with COPD symptoms, as 
assessed by the Serviço de Imunoalergologia, Hospital Dona Estefânia) have been collected.  
 
 Separation parameters 
Liquid chromatography: HALO C18, 2.7 µm, 90 Å, 0.5x50 mm column using a 30 min 
gradient from 5-95% B (solvent A: water + 0.1% FA; solvent B: Acetonitrile + 0.1% FA). 
Mass spectrometry: MS analysis was performed using a Sciex TripleTOF6600 with the 
DuoSpray Ion source. MS spectra accumulation time of 210 msec was used. 
 
 Data post-processing 
Data were further analysed using Finnee (https://finneeblog.wordpress.com/) a Matlab 
toolbox that aims in mining chromatographic peaks in LC-HRMS datasets in an untargeted 
approach. The following steps were used:  
1. The original files were converted to the mzML format using msConvert.  
2. mzML files were then transformed to Matlab objects, corrected for baseline drift and the 
background noise removed.3  
3. All profile MS scans were transformed to centroid MS scans. 
4. Chromatographic peaks were reconstructed from the raw data and chromatographic 
parameters calculated (migration time, intensity and accurate mass) and summarised in a 
peaks table for each datasets.  
5. Resulting peak tables were aligned and the intensity of all peaks input in a matrix.  
 
Description of steps Running 
Time  
Size  
Original file (wiff file) NA 
Conversion to mzML 15 min NA 
Conversion to Matlab Object 25 min 2.7 GB 
Baseline correction 35 min 1.0 GB 
Noise removal 15 min 8 MB 
Conversion of profile MS scans to 
centroid scans 
0.5 min 800 KB 
Mining for chromatographic features 
and characterization 
5 sec NA 
See 
Figure 2 
See 
Figure 3 
Table 1: Running time for the different computerised step for a single dataset (CPU: Intel 
Core i7 7700HQ @ 2.80GHz with 16.0GB of RAM) 
 
Figure 2: Total ion chromatogram from 
an asthmatic EBC sample  
Figure 3: Total ion chromatogram after 
correcting for baseline drift and background 
noise  
 Main achievements:  
 1200 to 1500 peaks per dataset 
  Intensities ranging from 500 to 5,000,000 
 After peaks matching, 1173 selected peaks (4 to 15 occurrences 
in all datasets) 
Figure 4: Variance weighted 
principal component analysis 
(PCA) using an intensity 
matrix with 15 observations 
(5 controls, 5 asthma and 5 
COPD) and 1173 variables 
(peak intensities). Intensities 
were normalised before the 
PCA by the sum of intensities 
for each observation.  
1 Lusuardi M, De Benedetto F, Paggiaro P, et al. A randomized controlled trial on office spirometry in asthma and COPD in 
standard general practice: data from spirometry in Asthma and COPD: a comparative evaluation Italian study. Chest 2006; 
129:844-52. 
2 Erny, GL, Acunha, T, Simó, C, Cifuentes, A, Alves, A. Finnee—A Matlab toolbox for separation techniques hyphenated high 
resolution mass spectrometry dataset. Chem. Int. Lab.; 155: 138-144. 
3 Erny, GL, Acunha, T, Simó, C, Cifuentes, A, Alves, A. Background correction in separation techniques hyphenated to high-
resolution mass spectrometry–Thorough correction with mass spectrometry scans recorded as profile spectra. J. Chrom. A; 
1492: 98-105 
Acknowledgements 
This work was financially supported by the projects: (i) POCI-01-0145-FEDER-006939 (Laboratory for Process Engineering, Environment, 
Biotechnology and Energy – UID/EQU/00511/2013) funded by the European Regional Development Fund (ERDF), through COMPETE2020 - 
Programa Operacional Competitividade e Internacionalização (POCI) and with financial support from FCT/MCTES through national funds 
(PIDDAC). (ii) NORTE‐01‐0145‐FEDER‐000005 – LEPABE-2-ECO-INNOVATION, supported by North Portugal Regional Operational 
Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the   European Regional Development Fund (ERDF).(iii) 
FEDER funds through the Operational Program for Human Potential and by National Funds through FCT under the project IF/00528/2013. (iv) 
AstraZeneca – Projecto OLDER (CEDOC/2015/59); (v) iNOVA4Health - UID/Multi/04462/2013, financially supported by FCT/Ministério da 
Educação e Ciência, and co-funded by FEDER under the PT2020 Partnership Agreement. 
References 
 Finnee allows extracting peak of very low intensity, ~1200 peaks whose 
intensities range four order of magnitudes were recover from each dataset; 
 After PCA, asthma, COPD and control EBCs samples were accurately 
differentiated, without any samples preparation techniques; 
  Simple and inexpensive sample pre-treatment techniques should be 
investigated to improve the quantity and quality of information; 
 Specific biomarkers should now be identified and fully characterised; 
 The study should be extended to include various asthma phenotypes and 
endotypes. 
Conclusions 
